Tomas
García-Caballero Parada
Universidade de Santiago de Compostela
Santiago de Compostela, EspañaPublicaciones en colaboración con investigadores/as de Universidade de Santiago de Compostela (132)
2024
-
Edoxaban treatment in a post-infarction experimental model
European Journal of Pharmacology, Vol. 962
-
Gastric GDF15 levels are regulated by age, sex, and nutritional status in rodents and humans
Journal of Endocrinological Investigation, Vol. 47, Núm. 5, pp. 1139-1154
2023
-
Immunohistological study of the density and distribution of human penile neural tissue: gradient hypothesis
International Journal of Impotence Research, Vol. 35, Núm. 3, pp. 286-305
-
Modification of the Marmarou and Foda model of diffuse axonal injury (DAI) improves percentage survival of rats at 24 h and increases the amount of DAI identified
Journal of Forensic Sciences, Vol. 68, Núm. 4, pp. 1228-1236
2022
-
A genome-wide cell-free DNA methylation analysis identifies an episignature associated with metastatic luminal B breast cancer
Frontiers in Cell and Developmental Biology, Vol. 10
-
Silver Clusters of Five Atoms as Highly Selective Antitumoral Agents Through Irreversible Oxidation of Thiols
Advanced Functional Materials, Vol. 32, Núm. 29
-
The Effect of Mineralocorticoid Receptor 3 Antagonists on Anti-Inflammatory and Anti-Fatty Acid Transport Profile in Patients with Heart Failure
Cells, Vol. 11, Núm. 8
-
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
Frontiers in Pharmacology, Vol. 13
2021
-
Correction to: Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2‑positive breast cancer? (Virchows Archiv, (2021), 479, 4, (853-857), 10.1007/s00428-021-03104-7)
Virchows Archiv
-
Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
Virchows Archiv, Vol. 479, Núm. 4, pp. 853-857
-
PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: Summary of an expert round-table discussion
Future Oncology, Vol. 17, Núm. 10, pp. 1209-1218
-
POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation
Oncogene, Vol. 40, Núm. 15, pp. 2725-2740
2020
-
An energy restriction-based weight loss intervention is able to reverse the effects of obesity on the expression of liver tumor-promoting genes
FASEB Journal, Vol. 34, Núm. 2, pp. 2312-2325
-
Author Correction: Identification and characterization of Cardiac Glycosides as senolytic compounds (Nature Communications, (2019), 10, 1, (4731), 10.1038/s41467-019-12888-x)
Nature Communications
-
Laser-induced transient skin disruption to enhance cutaneous drug delivery
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 156, pp. 165-175
-
Looking for a better characterization of triple-negative breast cancer by means of circulating tumor cells
Journal of Clinical Medicine, Vol. 9, Núm. 2
2019
-
Context-Dependent Impact of RAS Oncogene Expression on Cellular Reprogramming to Pluripotency
Stem Cell Reports, Vol. 12, Núm. 5, pp. 1099-1112
-
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats
Biochemical Pharmacology, Vol. 170
-
Identification and characterization of Cardiac Glycosides as senolytic compounds
Nature Communications, Vol. 10, Núm. 1
-
Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: Efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
Breast Cancer: Targets and Therapy, Vol. 11, pp. 29-42